Trans Genic Inc. announces an Equity Buyback for 550,000 shares, representing 3.17% for ¥300 million.
August 25, 2021 at 11:45 am IST
Share
Trans Genic Inc. (TSE:2342) announces a share repurchase program. Under the program, the company will repurchase up to 550,000 shares, representing 3.17% of its issued share capital for ¥300 million. The purpose of the program is agile capital policy implementation and shareholder return measures in response to changes in the business environment. The program is valid till December 24, 2021. As of August 25, 2021, the company had 17,367,719 shares issued (excluding treasury stock) and 1,422 shares in treasury.
TRANS GENIC INC. is a Japan-based company mainly engaged in the biotechnology business. The Company has three business segments. The Contract Research Organization (CRO) segment is engaged in the provision of contract clinical tests for pharmaceuticals and foods, pharmacodynamic pharmacology tests, safety pharmacology tests, pharmacokinetic tests, and non-clinical tests such as safety tests for pesticides and food, the contract production of genetically modified mice and antibody, the sale of model mice, as well as the development of new biomarkers. The Diagnostic Analysis segment is engaged in the provision of pathological diagnosis services, gene analysis contract services, and drug discovery support services for individualized medicine. The TGBS segment is engaged in the provision of advice and support services for business succession and revitalization in various fields, as well as the electronic commerce (EC) business such as the retail and wholesale of electrical products.